摘要
目的研究口服单一药物控制不良的2型糖尿病患者加用西格列汀的效果及安全性。方法择取2019年4月至2020年3月本院接收的96例2型糖尿病患者作为研究对象,根据随机数字表法将其分为对照组与观察组,各48例。对照组单一口服降糖药物治疗,观察组在对照组基础上加用西格列汀治疗。比较两组的血糖水平、胰岛素相关指标、炎性因子指标水平、氧化应激指标水平、神经病变主觉症状问卷(TSS)评分及用药安全性。结果治疗后,两组的FPG、2 h PG水平及HbA1c均低于治疗前,且观察组低于对照组(P<0.05)。治疗后,两组的FINS水平、HOMA-IR低于治疗前,HOMA-β高于治疗前,且观察组优于对照组(P<0.05)。治疗后,两组的CRP、IL-6、TNF-α水平低于治疗前,且观察组低于对照组(P<0.05)。治疗后,两组的MDA水平低于治疗前,SOD水平高于治疗前,且观察组优于对照组(P<0.05)。治疗后,两组的感觉异常、麻木、刺痛、灼烧感评分及总分均较治疗前降低,且观察组低于对照组(P<0.05)。观察组的不良反应总发生率低于对照组(P=0.011)。结论对口服单一药物控制不良的2型糖尿病患者加用西格列汀治疗不仅有助于血糖水平以及胰岛素相关指标的改善,还能减轻炎症反应以及氧化应激反应,具有较高的用药安全性及临床推广应用价值。
Objective To study the effect and safety of sitagliptin in patients with type 2 diabetes mellitus who are poorly controlled by oral single drugs.Methods A total of 96 patients with type 2 diabetes mellitus admitted in our hospital from April 2019 to March 2020 were selected as the study objects.According to the random number table method,the patients were divided into control group and observation group,with 48 cases in each group.The control group was treated with oral single hypoglycemic drugs,and the observation group was treated with sitagliptin on the basis of the control group.The blood glucose level,insulin related indexes,inflammatory factor index level,oxidative stress index level,neuropathy subjective symptom questionnaire(TSS)score and drug safety were compared between the two groups.Results After treatment,the levels of FPG,2 h PG and HbA1c in the two groups were lower than those before treatment,and those in the observation group were lower than the control group(P<0.05).After treatment,the level of FINS and HOMA-IR in the two groups were lower than those before treatment,HOMA-βwas higher than that before treatment,and those in the observation group were better than the control group(P<0.05).After treatment,the levels of CRP,IL-6 and TNF-αin the two groups were lower than those before treatment,and those in the observation group were lower than the control group(P<0.05).After treatment,the MDA level in the two groups was lower than that before treatment,and the SOD level was higher than that before treatment,and those in the observation group were better than the control group(P<0.05).After treatment,the scores of paresthesia,numbness,tingling,burning and total score in the two groups were lower than those before treatment,and those in the observation group were lower than the control group(P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group(P=0.011).Conclusion Adding sitagliptin in type 2 diabetes mellitus patients with poorly controlled by oral single drugs will not only help improve blood sugar levels and insulin related indexes,but also alleviate inflammation response and oxidative stress response,which has higher drug safety,clinical promotion and application value.
作者
石敏
张娜娜
王琼
赖敬波
刘向阳
SHI Min;ZHANG Nana;WANG Qiong;LAI Jingbo;LIU Xiangyang(Endocrinology Department,the First Affiliated Hospital of Air Force Military Medical University,Xi'an 710032,China)
出处
《临床医学研究与实践》
2022年第2期31-34,共4页
Clinical Research and Practice
关键词
2型糖尿病
西格列汀
血糖
type 2 diabetes mellitus
sitagliptin
blood sugar
作者简介
石敏(1982-),女,汉族,安徽马鞍山人,主治医师,硕士。研究方向:糖尿病及其慢性并发症的机制研究;通讯作者:刘向阳,E-mail:liuxy5@163.com.
